GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (GREY:VNAPF) » Definitions » Equity-to-Asset

Verona Pharma (Verona Pharma) Equity-to-Asset : 0.78 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Verona Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Verona Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $224.99 Mil. Verona Pharma's Total Assets for the quarter that ended in Mar. 2024 was $289.91 Mil.

The historical rank and industry rank for Verona Pharma's Equity-to-Asset or its related term are showing as below:

VNAPF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37   Med: 0.83   Max: 0.97
Current: 0.78

During the past 13 years, the highest Equity to Asset Ratio of Verona Pharma was 0.97. The lowest was 0.37. And the median was 0.83.

VNAPF's Equity-to-Asset is ranked better than
63.82% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs VNAPF: 0.78

Verona Pharma Equity-to-Asset Historical Data

The historical data trend for Verona Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Equity-to-Asset Chart

Verona Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.91 0.79 0.89 0.81

Verona Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.90 0.90 0.81 0.78

Competitive Comparison of Verona Pharma's Equity-to-Asset

For the Biotechnology subindustry, Verona Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verona Pharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Equity-to-Asset falls into.



Verona Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Verona Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=249.283/308.124
=

Verona Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=224.988/289.912
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verona Pharma  (GREY:VNAPF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Verona Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma (Verona Pharma) Business Description

Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.